Tarceva erlotinib: Complete Phase IIIb enrollment

This half, Genentech plans to complete enrollment of 1,150 patients with non-squamous NSCLC in the double-blind Phase IIIb ATLAS trial evaluating chemotherapy plus Avastin bevacizumab, followed by Av...